Talk:CVT-301

Notability concern
I haven't done an exhaustive search, but all the focus of the secondary (i.e., not NIH reports) sources I sampled is on the company's progress with it and its financial prospects associated with it rather than on the drug itself. Largoplazo (talk) 20:42, 10 February 2018 (UTC)